Main content area

Hemocompatibility and anti-fouling behavior of multilayer biopolymers immobilized on gold-thiolized drug-eluting cardiovascular stents B Biointerfaces

Huang, Li-Ying, Yang, Ming-Chien, Tsou, Hui-Ming, Liu, Ting-Yu
Colloids and surfaces 2019 v.173 pp. 470-477
adhesion, biocompatibility, biopolymers, blood coagulation, blood platelets, cell adhesion, chemical bonding, chondroitin, coatings, colloids, drug carriers, drugs, endothelial cells, gold, heparin, rapamycin, smooth muscle, stainless steel, thrombin, thrombosis
To solve the thrombosis and restenosis problem in cardiovascular stent implantation for cardiovascular artery disease, chondroitin 6-sulfate (ChS) with heparin (HEP) have been used as drug carrier layers and alternatively covalently bonded on gold (Au)-dimercaptosuccinic acid (DMSA)-thiolized cardiovascular metallic (SUS316 L stainless steel, SS) stents. Sirolimus, a model drug, was encapsulated in the ChS-HEP alternative layers. The behavior of the drug in releasing and suppressing the growth of smooth-muscle cells (SMCs) was evaluated with 5-layer CHS-HEP coating on the SS stents. Moreover, hemocompatibility of blood clotting time and platelet adhesion was performed. The results showed that the 5-layer ChS-HEP-modified SS stents displayed the greatest hemocompatibility, showing prolonged blood clotting time of the activated partial thrombin time (> 500 s) and less platelet adhesion to reduce thrombosis. Furthermore, sirolimus can be released continuously for more than 40 days with the 5-layer ChS-HEP coating and is beneficial for inhibiting the growth of SMCs; however, it does not affect the proliferation of endothelial cells, which can avoid restenosis formation. Therefore, the multilayers of ChS-HEP grafted onto the Au-DMSA-cardiovascular SS stents provide high potential for use as drug eluting stents.